Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M63,466Revenue (TTM) $M10,936Net Margin (%)33.8Altman Z-Score6.1
Enterprise Value $M66,422EPS (TTM) $16.3Operating Margin %47.1Piotroski F-Score5
P/E(ttm)17.8Beneish M-Score-3.0Pre-tax Margin (%)45.6Higher ROA y-yN
Price/Book6.210-y EBITDA Growth Rate %26.1Quick Ratio2.3Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %30.7Current Ratio2.6Lower Leverage y-yN
Price/Free Cash Flow20.3y-y EBITDA Growth Rate %17.3ROA % (ttm)19.9Higher Current Ratio y-yN
Dividend Yield %--PEG0.6ROE % (ttm)33.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M219ROIC % (ttm)33.5Gross Margin Increase y-yY

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBRonald Muhlenkamp 2016-03-31 Buy 2.53%$245.11 - $306.35
($264.69)
$ 289.739%New holding23,853
BIIBJoel Greenblatt 2016-03-31 Add0.62%$245.11 - $306.35
($264.69)
$ 289.739%Add 253.14%298,673
BIIBJohn Paulson 2016-03-31 Add0.16%$245.11 - $306.35
($264.69)
$ 289.739%Add 227.07%118,400
BIIBFirst Eagle Investment 2016-03-31 Add0.02%$245.11 - $306.35
($264.69)
$ 289.739%Add 15.83%224,585
BIIBKen Fisher 2016-03-31 Reduce-0.01%$245.11 - $306.35
($264.69)
$ 289.739%Reduce -18.17%90,405
BIIBRon Baron 2016-03-31 Add0.01%$245.11 - $306.35
($264.69)
$ 289.739%Add 56.71%16,047
BIIBMario Gabelli 2016-03-31 Add$245.11 - $306.35
($264.69)
$ 289.739%Add 0.10%4,810
BIIBJoel Greenblatt 2015-12-31 Add0.25%$256.04 - $309.67
($287.66)
$ 289.731%Add 798.80%84,577
BIIBFirst Eagle Investment 2015-12-31 Buy 0.15%$256.04 - $309.67
($287.66)
$ 289.731%New holding193,885
BIIBVanguard Health Care Fund 2015-12-31 Add0.09%$256.04 - $309.67
($287.66)
$ 289.731%Add 3.91%3,810,023
BIIBJohn Paulson 2015-12-31 Buy 0.07%$256.04 - $309.67
($287.66)
$ 289.731%New holding36,200
BIIBKen Fisher 2015-12-31 Reduce$256.04 - $309.67
($287.35)
$ 289.731%Reduce -1.75%110,475
BIIBMario Gabelli 2015-12-31 Add$256.04 - $309.67
($287.66)
$ 289.731%Add 0.17%4,805
BIIBRon Baron 2015-12-31 Reduce$256.04 - $309.67
($287.66)
$ 289.731%Reduce -13.32%10,240
BIIBVanguard Health Care Fund 2015-09-30 Add1.19%$272.28 - $409.5
($330.23)
$ 289.73-12%Add 105.96%3,666,723
BIIBJoel Greenblatt 2015-09-30 Buy 0.03%$272.28 - $409.5
($330.23)
$ 289.73-12%New holding9,410
BIIBKen Fisher 2015-09-30 Add0.02%$272.28 - $409.5
($330.23)
$ 289.73-12%Add 38.94%112,448
BIIBRon Baron 2015-09-30 Add$272.28 - $409.5
($330.23)
$ 289.73-12%Add 29.20%11,814
BIIBVanguard Health Care Fund 2015-06-30 Add1.17%$373.93 - $430.96
($401.66)
$ 289.73-28%Add 425.02%1,780,330
BIIBMario Gabelli 2015-06-30 Reduce$373.93 - $430.96
($401.66)
$ 289.73-28%Reduce -2.74%4,797
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCANGOS GEORGE ACEO 2016-05-25Sell157$2803.48view
SCANGOS GEORGE ACEO 2016-05-02Sell487$274.745.46view
Koppel AdamEVP, Strategy and Bus. Dev. 2016-04-06Sell102$2755.36view
SCANGOS GEORGE ACEO 2016-04-06Sell157$2803.48view
SCANGOS GEORGE ACEO 2016-04-01Sell487$258.8311.94view
SCANGOS GEORGE ACEO 2016-03-01Sell487$261.3710.85view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2016-02-25Sell183$261.910.63view
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff 2016-02-25Sell84$261.910.63view
SCANGOS GEORGE ACEO 2016-02-17Sell487$256.1613.11view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2016-02-17Sell722$256.1613.11view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about BIIB:

Articles On GuruFocus.com
Jeff Auxier's Spring 2016 Market Commentary May 20 2016 
Richard Snow Boosts Biogen, Keysight Technologies May 12 2016 
10 Years of Strong Returns: Priceline, Biogen Apr 26 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Undervalued Stocks With Wide Margin of Safety Apr 14 2016 
John Buckingham Trades in ETFs in 4th Quarter Mar 15 2016 
Widely Undervalued Stocks Trading Below Peter Lynch Value Feb 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Feb 10 2016 
Jean Hynes Finds Her Pot of Gold Jan 07 2016 

More From Other Websites
How to Discover the Best Biotechs in the World May 31 2016
Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS May 31 2016
FDA Approves Biogen and AbbVie's MS Treatment May 31 2016
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients... May 31 2016
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients... May 31 2016
12:30 am Biogen receives EU approval for FLIXABI May 30 2016
Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod May 30 2016
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union May 30 2016
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union May 30 2016
[$$] Once-Monthly MS Injection Approved in U.S. May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. approval May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval May 27 2016
Roche/Biogen Drug Gazyva Beats Rituxan In Cancer Trial May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... May 27 2016
Biogen (BIIB) Stock is the 'Chart of the Day' May 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. -... May 27 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)